Recalls of generic Zantac believed to be contaminated by a carcinogen continue to flood in. Two other firms have declared recalls of ranitidine heartburn meds in 150 mg and 300 mg doses. The news arrived even as the degree of the drug returns increased with Mylan’s impromptu recall of three lots of nizatidine capsules last week because the API in them also held dangerous levels of NDMA.
Shortly after the Federal officials announced the voluntary recalls of some pharmacies over NDMA, a drug filled with a potential human carcinogen, many other pharmacies have recalled the common variety of heartburn drug Zantac, called ranitidine, from shelves.
Additional generic editions of Zantac are being taken down from pharmacy shelves after officials detected low levels of a possible carcinogens in the heartburn medication.
The Stryker Tritanium Acetabular Shell, which restores the human hip socket, is built from a titanium alloy covered with a unique kind of porous foam. The foam enables bone cells to bind with it and grow, thereby increasing joint stability. However, a 2018 report in the journal Arthroplasty Today by doctors at NYU Langone Orthopedic Hospitals described five hip implant failures related to Stryker’s Tritanium cups between 2011 and 2016.
Securities industry regulatory body, FINRA (the Financial Industry Regulatory Authority), released its proposal for a rule that would crack down on firms with a high concentration of “bad” brokers. With its latest regulatory notice, FINRA stated that it would increase oversight of brokerages with a “significant history of misconduct,” requiring them to set aside additional funds that cannot be withdrawn without FINRA’s consent.
The financial industry self-regulator, FINRA, issued a new regulatory notice today aimed at broker-dealers with departing brokers. The notice was intended to urge broker-dealers to be more clear and forthright with customers about departing brokers and what will happen to the customers’ accounts. If you’ve ever been in the situation where your broker has either left for another firm, left the industry, or passed away, you understand just how confusing things can get when it comes to who will be handling your investments and why.
2332 South Broad Street
Philadelphia PA 19145
p: 215 462 3330 / f: 215-567-1941
